ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Respiratory Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1533634
Active Surveillance of Adverse Drug Events in Hospitalized Patients with Pulmonary Arterial Hypertension Based on the Global Trigger Tool
Provisionally accepted- 1School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China
- 2Department of Pharmacy,, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China
- 3Department of Pharmacy, Maoming Hospital of Traditional Chinese Medicine, Maoming, China
- 4Guangzhou Pinyi Information Technology Co., Guangzhou, Guangdong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To explore the method of active monitoring of adverse drug events (ADEs) in patients with a rare disease: pulmonary arterial hypertension (PAH).Methods: First, initial trigger items were extracted and organized through literature-based evidence and drug inserts. Then, the trigger items were refined using expert consultation based on a Delphi method. Second, patients with PAH admitted to a hospital between 1 January 2022 and 1 June 2023 were extracted as study samples. A retrospective case review was conducted to verify the clinical applicability of triggers. We calculated indicators such as sensitivity, specificity, and positive predictive value (PPV), and also observed the ADEs. Risk factors for the development of ADEs in hospitalized patients with PAH were also analyzed.We extracted and organized 31 initial trigger items. After two rounds of modification through expert consultation, 24 triggers were identified. We converted the trigger items into risk signals to automatically identify cases with possible ADEs with the help of the Chinese Hospital Pharmacovigilance System (CHPS). Manual review of suspected cases revealed that the overall PPV of the triggers was 30.30%, the sensitivity was 98.21%, and the specificity was 72.57%. The prevalence of ADEs detection was 17.57%, which was equivalent to 25.75 ADEs occurrences in 1000 patient days and 11.84 ADEs occurrences in 1000 medications. ADEs-involved organs included the blood system, and there was also damage to the gastrointestinal system, hepatic system, and renal system. ADEs severity was categorized into 24 grade D cases, 102 grade E cases, 15 grade F cases, and two grade H cases. The longer the duration of hospitalization, the higher the number of comorbidities, the higher the number of positive triggers, and the higher the likelihood of ADEs.This study provides a new method for actively identifying ADEs in hospitalized patients with PAH, as well as a reference for research on pharmacovigilance for rare diseases.
Keywords: Global Trigger Tool, pulmonary arterial hypertension, Adverse drug events, Active monitoring, Chinese Hospital Pharmacovigilance System
Received: 24 Nov 2024; Accepted: 04 Jul 2025.
Copyright: © 2025 Xu, He, Li, Xiong and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Suzhen He, Department of Pharmacy,, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510175, Guangdong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.